The United Kingdom and the United States have secured a important trade agreement that will keep no levies on UK drug shipments being sold in the American market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has agreed to increase funding on drugs through the National Health Service (NHS). This commitment ensures that tariffs on these vital goods will be held at zero for a period of three years.
This deal follows recent statements to significantly raise tariffs on patented pharmaceutical products, with figures mentioned as high as 100%.
"This agreement between the UK reinforces the global environment for innovative medicines and introduces long-overdue fairness to American-British drug exports," a statement said.
Economic Significance
Drugs are one of the Britain's biggest export categories to the America, which is clearly the largest market for large companies like GSK and AstraZeneca.
Export figures indicate that in the year to the end of last September, the UK exported pharmaceutical products worth billions to the US. This amount represented nearly one-fifth of total UK exports in that span.
"This agreement protects employment, increases capital expenditure and paves the way for the UK to become a worldwide center for biotech and pharma," a government official commented.
Specific UK Commitments
The pact includes several specific changes from the UK:
- Price Threshold Increase: The UK will increase the price threshold at which it deems new therapies to be too expensive by a quarter.
- Boosted Medicine Funding: There is a aim to raise total public funding on medicines from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The amount pharmaceutical firms must return to the NHS to stay within budget will be capped at fifteen percent. Previously, refunds exceeded 20%.
Broader Context
The pact takes place against a ongoing dispute between the pharmaceutical industry and the ministers over spending levels and regulatory access.
These tensions were exacerbated by assertions that US customers were charged a premium for the same drugs than patients in the Britain and the EU.
Over the last 18 months, several significant drug company projects in the UK have been paused or scrapped, while substantial investments have been directed toward American operations.
The Science Minister stated that the NHS must invest a greater share on medicines, noting that its budget allocation on drugs had decreased as a share of its resources over the last ten years.
